We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A medical nutriment has supportive value in the treatment of colorectal cancer.
- Authors
Jakab, F; Shoenfeld, Y; Balogh, A; Nichelatti, M; Hoffmann, A; Kahán, Zs; Lapis, K; Mayer, A; Sápy, P; Szentpétery, F; Telekes, A; Thurzó, L; Vágvölgyi, A; Hidvégi, M
- Abstract
MSC (Avemar) is a medical nutriment of which preclinical and observational clinical studies suggested an antimetastatic activity with no toxicity. This open-label cohort trial has compared anticancer treatments plus MSC (9 g once daily) vs anticancer treatments alone in colorectal patients, enrolled from three oncosurgical centres; cohort allocation was on the basis of patients' choice. Sixty-six colorectal cancer patients received MSC supplement for more than 6 months and 104 patients served as controls (anticancer therapies alone): no statistical difference was noted in the time from diagnosis to the last visit between the two groups. End-point analysis revealed that progression-related events were significantly less frequent in the MSC group (new recurrences: 3.0 vs 17.3%, P<0.01; new metastases: 7.6 vs 23.1%, P<0.01; deaths: 12.1 vs 31.7%, P<0.01). Survival analysis showed significant improvements in the MSC group regarding progression-free (P=0.0184) and overall survivals (P=0.0278) probabilities. Survival predictors in Cox's proportional hazards were UICC stage and MSC treatment. Continuous supplementation of anticancer therapies with MSC for more than 6 months is beneficial to patients with colorectal cancer in terms of overall and progression-free survival.
- Publication
British journal of cancer, 2003, Vol 89, Issue 3, p465
- ISSN
0007-0920
- Publication type
Journal Article
- DOI
10.1038/sj.bjc.6601153